Anthony O. Caggiano

Chief Medical Officer at CogRx

Dr. Caggiano is broad-based therapeutic development executive with experience across a range of disease indications, including neurological disorders. Prior to joining Cognition Therapeutics, Dr. Caggiano was acting president and chief medical officer of Constant Pharmaceuticals and Aeromics, Inc., clinical-stage companies respectively developing candidates for central nervous system disorders and cerebral edema following ischemic stroke. Earlier, as senior vice president of research and development at Acorda Therapeutics, he oversaw a staff managing clinical and preclinical research and development programs in multiple sclerosis, spinal cord injury and other neurological disorders.
By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.